Merck Unveils Promising Early Data for MK-1045 and Bomedemstat in Hematologic Cancers at ASH 2025

Merck & Co., Inc. +0.46% Post

Merck & Co., Inc.

MRK

120.84

120.84

+0.46%

0.00% Post

Merck & Co. Inc. announced that new data from its hematology pipeline will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in December 2025. The company will share results from multiple investigational therapies, including the first clinical presentation of MK-1045, a novel CD19xCD3 T-cell engager, in adults with relapsed or refractory B-cell acute lymphoblastic leukemia. Additionally, Merck will present initial results from the Phase 2 Shorespan-004 study of bomedemstat (MK-3543), an LSD1 inhibitor, in patients with polycythemia vera who are resistant or intolerant to cytoreductive therapy. Updated data on nemtabrutinib (MK-1026), a non-covalent BTK inhibitor, and zilovertamab vedotin (MK-2140), an antibody-drug conjugate targeting ROR1, are also scheduled for presentation. The results have not yet been presented and will be disclosed at the ASH 2025 meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251124225525) on November 24, 2025, and is solely responsible for the information contained therein.
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.